Cancer Registration: Principles and Methods - IARC

More documents

Recommendations

Info

216 Appendix 2 Table 1 - continued (Note: the edits described below refer to the 1976edition of ICD-0) Field A Field B Editing criteria Item name1 Item name1 Follow-up status Cause of death (item If follow-up status is alive, then cause of death must be (item 31) 33) 0000 (alive); if follow-up status is dead, then cause of death must not be 0000 Date of last contact Date cancer-directed Date of cancer-directed therapy must be the same as or (item 30) therapy started before date of last contact. The item numbers in parentheses refer to the corresponding items of patient information described in Chapter 6 SEER sitelhistology validation edit When both the site and the histological type (including behaviour code) are found to be valid, a siteltype combination edit will be performed. The siteltype edit checks for allowable histology codes for each site. The sitelhistology validation list designates each site and the histology codes (four-digit) that are considered valid for each sitean example, for lip cancer, is shown in Table 2. The list frequently specifies ranges of site codes but only valid site codes within the range are applicable. The histology terms on the sitelhistology validation list are not necessarily the preferred terms specified in the International Classification of Diseases for Oncology (ICD-0). A diagnostic message will be generated for those cases for which the histology code is not specified as valid for the site code. If, after review of the case, the site/histology combination is found to be correct, the override flag should be set to 'on'. In addition, the following combinations are invalid: (1) An unknown or ill-dejned site with a histology that has an in situ behaviour code: 149.9 Ill-defined sites in lip, oral cavity and pharynx 159.9 Ill-defined sites within digestive organs and peritoneum 165.9 Ill-defined sites within respiratory system 179.9 Uterus, NOS 184.9 Female genital tract, NOS 187.9 Male genital tract, NOS 189.9 Urinary system, NOS 192.9 Nervous system, NOS 194.9 Endocrine gland, NOS 195.- Other ill-defined sites 199.9 Unknown primary site (2) Ill-dejned sites (1 95 .-) with histologies specifying melanoma (M8 720-8 790)
Table 2. Example of a SEER site/histology validation list -- -- - Site ---- Histology (four-digit) Lip 400-409 800013 Neoplasm, malignant 800113 Tumor cells, malignant 800213 Malignant tumor, small cell type 800313 Malignant tumor, giant cell type 800413 Malignant tumor, fusiform cell type 80 1012 Carcinoma-in-situ, NOS 801013 Carcinoma, NOS 801 113 Epithelioma, malignant 801213 Large cell carcinoma, NOS 802013 Carcinoma, undifferentiated type, NOS 802113 Carcinoma, anaplastic type, NOS 802213 Pleomorphic carcinoma 803013 Giant cell and spindle cell carcinoma 803113 Giant cell carcinoma 803213 Spindle cell carcinoma 803313 Pseudosarcomatous carcinoma 803413 Polygonal cell carcinoma 805012 Papillary carcinoma-in-situ 805013 Papillary carcinoma, NOS 805 113 Verrucous carcinoma, NOS 805213 Papillary squamous cell carcinoma 807012 Squamous cell carcinoma-in-situ, NOS 807013 Squamous cell carcinoma, NOS 807113 Sq. cell carc., ker. type, NOS 807213 Sq. cell carc., lg. cell, non-ker. 807313 Sq. cell carc., sm. cell, non-ker. 807413 Sq. cell carc., spindle cell 807513 Adenoid squamous cell carcinoma 807612 Sq. cell carc.-in-situ 807613 Sq. cell carc., micro-invasive 808112 Bowen's disease 808213 Lymphoepithelial carcinoma 8 14012 Adenocarcinoma-in-situ 814013 Adenocarcinoma, NOS 8 14113 Scirrhous adenocarcinoma 814313 Superficial spreading adenoca. 820013 Adenoid cystic carcinoma 820113 Cribriform carcinoma 826013 Papillary adenocarcinoma, NOS 826112 Adenoca. in situ in villous adenoma 826113 Adenocarcinoma in villous adenoma 826213 Villous adenocarcinoma Appendix 2 21 7 826312 Adenoca. in situ in tubulovillous adenoma 826313 Adenocarcinoma in tubulovillous adenoma
Page 2 and 3:
WORLD HEALTH ORGANIZATION INTERNATI
Page 4 and 5:
Contents Foreword .................
Page 6 and 7:
Foreword The maintenance of a regis
Page 8 and 9:
2 Introduction and an increased exp
Page 10 and 11:
4 G. Wagner the first time to elimi
Page 12 and 13:
6 G. Wagner International Symposium
Page 14 and 15:
8 0. M. Jensen and H.H. Storm made
Page 16 and 17:
k d Table 2. Worldwide variation in
Page 18 and 19:
O.M. Jensen and H.H. Storm Hodgkin
Page 20 and 21:
O.M. Jensen and H.H. Storm ~i~ure 2
Page 22 and 23:
16 O.M. Jensen and H.H. Storm 1oo.0
Page 24 and 25:
0. M. Jensen and H. H. Storm Figure
Page 26 and 27:
O.M. Jensen and H.H. Storm -44 year
Page 28 and 29:
Chapter 4. Planning a cancer regist
Page 30 and 31:
24 0. M. Jensen and S. Whelan parti
Page 32 and 33:
26 0. M. Jensen and S. Whelan Numbe
Page 34 and 35:
28 0. M. Jensen and S. Whelan Concl
Page 36 and 37:
30 J. Powell sources, firstly, to p
Page 38 and 39:
32 J. Powell reports. If a histolog
Page 40 and 41:
34 J. Powell needs but conserving t
Page 42 and 43:
36 J. Powell Health insurance (work
Page 44 and 45:
38 J. Powell episodes-that is, with
Page 46 and 47:
The disadvantages are : - the quali
Page 48 and 49:
42 J. Powell (c) medical doctors in
Page 50 and 51:
44 R. MacLennan Table 1. Basic info
Page 52 and 53:
codes (population groups, occupatio
Page 54 and 55:
48 R. MacLennan morphology (item 21
Page 56 and 57:
50 R. MacLennan or convention to th
Page 58 and 59:
facilities and to the acceptance of
Page 60 and 61:
54 R . MacLennan second generation
Page 62 and 63:
56 R. MacLennan Item 18 : Certainty
Page 64 and 65:
2. Carcinoma in situ Intraepithelia
Page 66 and 67:
code allocated as item 20 should re
Page 68 and 69:
Hospital registries will wish to el
Page 70 and 71:
Chapter 7. Classification and codin
Page 72 and 73:
66 C.S. Muir and C. Percy Primarily
Page 74 and 75:
68 C.S. Muir and C. Percy obtained
Page 76 and 77:
70 C.S. Muir and C. Percy Topograph
Page 78:
Table 2. Coding of selected cancers
Page 81 and 82:
CIassification and coding of neopla
Page 83 and 84:
CIassiJication and coding of neopla
Page 85 and 86:
ClassiJication and coding of neopla
Page 87 and 88:
Class$cation and coding of neoplasm
Page 89 and 90:
Manual and computerized cancer regi
Page 91 and 92:
New notification I Manual and compu
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Disk storage Manual and computerize
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Chapter 9. Quality and quality cont
Page 109 and 110:
Quality and quality control 103 It
Page 111 and 112:
Consistency checks Quality and qual
Page 113 and 114:
Standards Quality and quality contr
Page 115 and 116:
0. M. Jensen and H. H. Storm 109 th
Page 117 and 118:
Reporting of results 111 Evaluation
Page 119 and 120:
Reporting of results 113 should giv
Page 121 and 122:
171 Connective tiaaue 1 3 5 11 10 1
Page 123 and 124:
- 0 - 0 - m o m m L O N I O I O O o
Page 125 and 126:
Reporting of results Number of case
Page 127 and 128:
Reporting of results Figure 5. Age-
Page 129 and 130:
Reporting of results Dlgestlve orga
Page 131 and 132:
Reporting of results Year of diagno
Page 133 and 134:
Statistical methods for registries
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Chapter 12. Analysis of survival D.
Page 167 and 168:
Passive follow-up Analysis of survi
Page 169 and 170:
Analysis of survival Table 1 - cont
Page 171 and 172: Table 2. Calculation of observed su
Page 173 and 174: Table 3. Calculation of the correct
Page 175 and 176: Analysis of survival 169 Table 4. C
Page 177 and 178: Analysis of survival 171 In the cal
Page 179 and 180: Analysis of survival 1 73 Table 6.
Page 181 and 182: Analysis of survival Deaths : cases
Page 183 and 184: Chapter 13. The hospital-based canc
Page 185 and 186: The hospital-based cancer registry
Page 191 and 192: Chapter 14. Cancer registration in
Page 193 and 194: Cancer registration in developing c
Page 205 and 206: Chapter 15. Cancer registration: le
Page 207 and 208: Cancer registration: legal aspects
Page 209 and 210: Computer Cancer registration : lega
Page 211 and 212: Cancer registration: legal aspects
Page 213 and 214: Cancer registration : legal aspects
Page 215 and 216: Appendix I Botswana Brazil British
Page 217 and 218: Appendix 1 Sri Lanka Sudan Suriname
Page 219 and 220: Appendix 2 213 Some of these edits
Page 221: Appendix 2 Table 1 - continued (Not
Page 225 and 226: - Appendix 2 219 Follow-up status (
Page 227 and 228: Appendix 3(a) 221 (c) statistics on
Page 229 and 230: Appendix 3(a) 223 presence of tumou
Page 231 and 232: Appendix 3(a) the hospital record.
Page 233 and 234: Appendix 3(a) 227 REVERSE SIDE OF N
Page 235 and 236: Appendix 3(a) REVERSE SIDE OF NOTIF
Page 237 and 238: Data from CPR, i.e. vital Warning o
Page 239 and 240: Appendix 3(a) 233 place of residenc
Page 241 and 242: Appendix 3(a) 235 maintained for ta
Page 243 and 244: Appendix 3 (b) The Thames Cancer Re
Page 245 and 246: SURGERY Appendix 3(b) TREATMENT OF
Page 247 and 248: Appendix 3(b) 241 supervised by the
Page 249 and 250: Appendix 3(b) 243 first for direct
Page 251 and 252: Appendix 3(b) 245 maintaining an ef
Page 253 and 254: Appendix 3(c) 247 information on ca
Page 255 and 256: Appendix 3(c) 249 Pathology reports
Page 257 and 258: Appendix 3(c) HOSPITAL DISCHARGES L
Page 259 and 260: Appendix 3(c) Table 1. Groupings of
Page 261 and 262: Appendix 3(c) 255 several sources a
Page 263 and 264: Appendix 3(c) 257 resulted in a can
Page 265 and 266: Appendix 3(d) medical records (in-p
Page 267 and 268: Appendix 3(d) MOST VALID BASIS OF D
Page 269 and 270: Appendix 3(d) 263 -malignancies usu
Page 271 and 272: Appendix 3(d) abstract. For recorde
Page 273 and 274:
Appendix 4. CANREG: Cancer registra
Page 275 and 276:
Appendix 4 Table 1. CANREG internal
Page 277 and 278:
Appendix 4 271 0 Page 1 Patient Nam
Page 279 and 280:
Appendix 4 273 -an operating system
Page 281 and 282:
References Acheson, E. D. (1967) Me
Page 283 and 284:
References 277 oncology services. T
Page 285 and 286:
References International Agency for
Page 287 and 288:
References 281 Official Statistics
Page 289 and 290:
References 283 Sieveking, G. H. (19
Page 291 and 292:
Subject Index Access to data, 202,
Page 293 and 294:
Subject Index International Classif
show all

Cancer Registration: Principles and Methods - IARC

Create successful ePaper yourself

Delete template?

Save as template?